<DOC>
	<DOCNO>NCT02377349</DOCNO>
	<brief_summary>The purpose study assess immunogenicity safety Boostrix™ compare placebo give 27-36 week gestation healthy woman age 18-45 year . Infants born mother enrol study followed-up two separate clinical study : 201330 [ DTPA ( BOOSTRIX ) -048 PRI ] 201334 [ DTPA ( BOOSTRIX ) -049 BST : 048 ] .</brief_summary>
	<brief_title>Immunogenicity Safety Study GlaxoSmithKline ( GSK ) Biologicals ' Boostrix™ Vaccine Pregnant Women</brief_title>
	<detailed_description>The protocol amend include Spain study . The reason Spain-specific amendment list : - Based feedback Spanish Ethics Committee , evaluation relate acceptance cocoon add protocol . - The objective endpoint include cocoon add protocol . - The eligibility criterion participation household contact define protocol . - The study procedure household contact include .</detailed_description>
	<mesh_term>Diphtheria</mesh_term>
	<criteria>Inclusion Criteria study subject : Subjects , opinion investigator , comply requirement protocol . Written inform consent obtain subject prior perform study specific procedure , per local regulation . A healthy pregnant woman , include , 18 45 year age time screen . Pregnant subject 27 0/736 6/7 week ( complete 27 week 37 week ) gestation time vaccination ( Visit 1 ) , establish ultrasound examination . Not high risk complication , determine obstetrical algorithm identification eligible subject Obstetrical Risk Assessment Form . No significant foetal abnormality , observe level II ultrasound test conduct 18 week gestation . Nuchal translucency scan , serum test prenatal test , conduct , suggest normal pregnancy . Willing infant born immunise Infanrix hexa Prevenar 13 , per national recommendation , followup clinical study DTPA ( BOOSTRIX ) 048 PRI DTPA ( BOOSTRIX ) 049 BST : 048 . Subjects plan give child adoption place child care . Inclusion criterion household contact Spain : Household contact live house infant . Household contact parent ( ) /LAR ( ) household contact , opinion investigator , comply requirement protocol ( e.g . report SAEs ) . Written inform consent obtain household contact parent ( ) /LAR ( ) prior vaccination , per local regulation . Household contact eligible receive booster dose DTPcontaining vaccine accord Summary Product Characteristics ( SmPC ) Boostrix accord local governmental recommendation Spain . Female household contact nonchildbearing potential may enrol study . Nonchildbearing potential define premenarche , current tubal ligation , hysterectomy , ovariectomy postmenopause . Female household contact childbearing potential may enrol study , household contact practice adequate contraception 30 day prior vaccination , negative pregnancy test day vaccination agree continue adequate contraception 2 month receive vaccine dose . Exclusion Criteria study subject : Subjects diagnose multiple pregnancy ( twin , triplet etc. ) . Previous vaccination contain diphtheria , tetanus pertussis antigen diphtheria tetanus toxoid time current pregnancy . Women comorbid medical obstetric condition opinion investigator potential complicate pregnancy course outcome . Gestational diabetes determine glucose tolerance test conduct 20 week gestation , per local recommendation country . History early onset ( &lt; 34 week gestation ) eclampsia/preeclampsia previous pregnancy . History major congenital anomaly previous pregnancy . Use investigational nonregistered product ( drug vaccine ) study vaccine anytime current pregnancy plan use study period . Any medical condition judgment investigator would make intramuscular injection unsafe . Chronic administration immunosuppressant immunemodifying drug period start six month prior first vaccine . For corticosteroid , mean prednisone ≥20 mg/day , equivalent . Inhaled topical steroid allow . Administration longacting immunemodifying drug time study period . Planned administration/administration vaccine foreseen study protocol period within period start 30 day 30 day dose vaccine exception seasonal influenza vaccine administer anytime study period . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational vaccine/product ( pharmaceutical product device ) . Serious underlie medical condition [ e.g. , immunosuppressive disease therapy , human immunodeficiency virus infection , collagen vascular disease , epilepsy , diabetes mellitus , chronic hypertension , moderate severe asthma , lung/heart disease , liver/kidney disease , infection include TORCHES ( toxoplasmosis , rubella , cytomegalovirus , herpes simplex , syphilis ) infection ] . History encephalopathy unknown aetiology , occur within 7 day follow previous vaccination pertussiscontaining vaccine . History transient thrombocytopenia neurological complication ( convulsion hypotonichyporesponsive episode ) follow early immunisation diphtheria and/or tetanus Significant mental illness ( e.g . schizophrenia , psychosis major depression ) . Family history ( first degree relative ) congenital anomaly , recurrent pregnancy loss ( two consecutive loss ) unexplained neonatal death ( ) subject . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination ( laboratory testing require ) . History reaction hypersensitivity likely exacerbate component vaccine . History febrile illness within past 72 hour . History physiciandiagnosed laboratoryconfirmed pertussis within past five year . Anything would prevent subject complete study put subject risk , determine investigator . Acute disease and/or fever time enrolment . Fever define temperature ≥ 37.5°C /99.5°F oral , axillary tympanic route , ≥ 38.0°C /100.4°F rectal route . Subjects minor illness ( mild diarrhoea , mild upper respiratory infection ) without fever may enrol discretion investigator . Administration immunoglobulins and/or blood product within 3 month precede dose study vaccine , plan administration study period , exception antiD ( Rh ) immunoglobulin . History chronic excessive alcohol consumption and/or drug abuse . Exclusion criterion household contact Spain : Child care . Concurrently participate another clinical study , time study period , household contact expose investigational noninvestigational product ( pharmaceutical product device ) . Use investigational nonregistered product ( drug vaccine ) study vaccine within 30 day precede dose study vaccine , plan use study period . History reaction hypersensitivity likely exacerbate component vaccine . History encephalopathy unknown aetiology , occur within 7 day follow previous vaccination pertussiscontaining vaccine . Acute disease and/or fever time enrolment . Fever define temperature ≥ 37.5°C /99.5°F oral , axillary tympanic route , ≥ 38.0°C /100.4°F rectal route . The preferred route record temperature axillary household contact . Household contact minor illness ( mild diarrhoea , mild upper respiratory infection ) without fever may enrol discretion investigator . Anything would put household contact risk , determine investigator . Pregnant lactate household contact . Household contact plan become pregnant planning discontinue contraceptive precaution prior 2 month postvaccination .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>